CCRM Australia supports increased cooperation between existing regenerative medicine service providers

The Centre for Commercialization of Regenerative Medicine Australia (CCRM Australia) is proud to announce the formation of a platform providing a single touch point for comprehensive delivery of cell and gene therapy solutions. The Australian Alliance of Cell and Gene Therapy (AACGT) is a consortium of partners with complementary domain expertise throughout the cell and gene therapy value chain and an extensive network of partners to provide a complete service. These services include:

  • Pre-clinical proof of concept studies, product development expertise, & pilot manufacturing
  • GMP process development, manufacturing and distribution for clinical and commercial uses
  • Clinical trial protocol development, IRB/Ethical approval, implementation and execution
  • Commercialisation expertise

The alliance consists of current CCRM Australia members Cell Therapies Pty Ltd, the CRC For Cell Therapy Manufacturing and St Vincent’s Hospital Melbourne (along with CCRM Australia). We will see the partners cooperating to provide a comprehensive ‘end to end’ solution for researchers and companies requiring specialised cell and gene therapy related services.

Together, the alliance partners provide a comprehensive suite of services. This ranges from proof of concept and testing services, upscaling and GMP production for clinical trials, assistance with design, approval and implementation of clinical trials, through to commercialisation. Access to a comprehensive network of universities, research organisations, health services for trials and commercial providers with the relevant capabilities throughout Australia is the hallmark of this alliance.

CCRM Australia CEO, Mr Silvio Tiziani stated “CCRM Australia has been established to help accelerate the commercialization of Australian regenerative medicine therapies and related products. We do this by fostering more collaboration between industry, clinicians and academia; and nurturing local regenerative medicine companies for the international market. The alliance is a perfect example of how we can do this –by harnessing the skills and expertise of existing service providers to offer a more comprehensive service.”

“From the commercial operations point of view, this alliance provides researchers with an efficient conduit into the complex machinery needed to bring pre-clinical projects out of the lab and into the clinic” commented CEO of Cell Therapies Pty Ltd, Dr Dawn Driscoll. “Cell and gene therapies are being developed for a variety of medical conditions, including the most intractable diseases. Through the AACGT alliance, we will be able to speed up this long development process and bring these life saving therapies to patients more efficiently.”

“The End2End solution offered by the alliance partners is designed to provide easy access to expertise at all stages of development, translation and commercialisation of new regenerative medicine therapies” commented the Director of Research at St Vincent’s Hospital Melbourne, Dr Megan Robertson. “St Vincent’s Hospital Melbourne is excited to be part of this new alliance, enabling our clinicians, patients and community the opportunity to participate in state-of-the-art clinical trials, ensuring these important new discoveries and developments get to clinical care more rapidly.”

“The challenge of bringing a therapy to market requires a broad array of skills, knowledge and infrastructure” commented CEO and Chair of CRC for Cell Therapy Manufacturing, Dr Leanna Read. “The Australian regenerative medicine industry is small and the ability to leverage the skills and capabilities across the network of organisations within the AACGT alliance will have a tremendous impact on supporting emerging cell therapy companies in this region. The ability to more rapidly translate their products into the clinic will make these companies more globally competitive and position Australia as a leader in this maturing industry.”

Alliance partners encourage other Australian service providers with complementary expertise in the cell and gene therapy sector to contact us to discuss how your organisation can also contribute to the service offerings provided by the Australian Alliance of Cell and Gene Therapy (AACGT).

About CCRM Australia

CCRM Australia is an Australian not-for-profit organisation supporting the development of foundational technologies to accelerate the commercialisation of regenerative medicine products and therapies.

CCRM Australia’s focus is to bridge the commercialisation gap through a network of scientists, entrepreneurs, academic institutions and industry partners and address bottlenecks in the industry.

Modelled on the highly successful Centre for Commercialization of Regenerative Medicine (CCRM) based in Canada, CCRM Australia is a leader in developing and commercializing regenerative medicine, cell and gene technologies. Drawing from the organisation’s expertise and industry and capital venture networks established over a five-year period, CCRM Australia is poised to take a leading role in supporting Australia’s fast developing regenerative medicine sector.

About the CRC for Cell Therapy Manufacturing

The CRC for Cell Therapy Manufacturing (CTM CRC) is an international collaboration of 16 participant organisations spanning industry, clinicians, healthcare and research providers.

A $60M investment from the Australian Government and CTM CRC’s participants enables CTM CRC to connect cell biology with advanced materials in a unique approach to address the challenges in regenerative medicine today. Through this, CTM CRC is developing integrated solutions for cost effective, accessible cell therapies.

CTM CRC is part of the Australian Government’s Cooperative Research Centres (CRC) Programme. The CRC Programme aims to foster high quality research to solve industry-identified issues through industry-led and outcome-focused collaborative research partnerships.

About Cell Therapies Pty Ltd (CTPL)

CTPL is a leading global contract manufacturer and distributor of cellular therapies. The company specializes in developing world-class solutions to deliver cellular therapies for clinical trials, special access and approved commercial uses. Located in the Peter MacCallum Cancer Centre (“Peter Mac”) in Melbourne, Australia, CTPL are the most experienced contract manufacturer in the Asia Pacific region with over 15 years of GMP manufacturing and product distribution to meet many international regulatory agency requirements (including Australia’s TGA, US FDA, and Europe’s EMA).

About St Vincent’s Hospital Melbourne

St Vincent’s Hospital Melbourne is one of five tertiary teaching hospitals in Victoria with respected clinical education and research programs. Our clinical care is supported by an inspiring and very active translational research program with a unique focus on biomedical engineering as well as extensive biotech and pharmaceutical research.

Our unique Research Valet Service provides fast facilitated IRB submission and review (with National Mutual Acceptance credentialing) so that our IRB review is accepted across Australia in both private and public health facilities.

St Vincent’s Hospital Melbourne is part of the St Vincent’s Health Australia (SVHA), a $2 billion not-for-profit health and aged care provider. SVHA is the 12th largest private company in the country, and the second largest healthcare provider with more than 30 facilities along the eastern seaboard.

For further information please contact:

Dr Emma Gallaher (CCRM Australia):

T: +61 438 639 878

Dr Tony Simula (Manager, Development & Commercialisation, CTM CRC)

T: +61 8 8302 3491 or +61 435 949 868

Nathan Smith (Project Portfolio Manager, Cell Therapies)

T: +61 3 8559 7321 or +61 477 738 404

Dr Megan Robertson (Director of Research, St Vincent Hospital Melbourne)

T: +61 3 9288 3895

View the Australian Alliance for Cell and Gene Therapy flyer.